Kla Corp
$246.77B- Market cap
- $242.53B
- Debt
- +$5.89B
- Cash
- −$1.65B
Capital structure 98% equity / 2% debt · EV / Revenue 18.17x · EV / EBITDA 39.21x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt capMarket cap $242.53B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: KLAC stock price at premium vs ANIK $185.63 current versus $25.68 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ANIK's multiple
Implied fair value · at KLAC's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: KLAC FY 2026 (ended Jun 30, 2026) · ANIK FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
11 fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 98% equity / 2% debt · EV / Revenue 18.17x · EV / EBITDA 39.21x
Capital structure 100% equity / -0% debt · EV / Revenue 1.75x
KLAC carries the larger enterprise value at $246.77B against $197.45M; ANIK trades on the lower EV / Revenue multiple (1.75x vs 18.17x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
KLA CORP · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Anika Therapeutics, Inc. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.93x
-0.00x
Net debt / EBITDA
Leverage against operating earnings
0.67x
34.65x
Cash and equivalents
Liquid reserves on the balance sheet
$1.65B
$81.17M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
$5.89B
-$149.00K
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.